"First, they were diabetes drugs. Then, weight loss blockbusters. Now, scientists believe they have identified another potential benefit of injectable GLP-1 drugs like Ozempic and Mounjaro: fewer colon cancer deaths. In a recent study, researchers at the University of California discovered that colon cancer patients who happened to be taking a GLP-1 drug like Ozempic or Mounjaro cut their risk of death in half over a five-year period."
"Professor Raphael Cuomo, lead author of the new research, said his team tried to find other explanations for the trend. Perhaps the people who weren't taking GLP-1s had other health issues, like depression or kidney disease, impacting their chance of survival. Nothing stuck. Even when controlling for all of those issues and more, there was "still a consistent, significant association between GLP-1 drug use in colon cancer patients and improved survival," Cuomo said."
Colon cancer patients taking GLP-1 drugs such as Ozempic and Mounjaro experienced roughly half the five-year mortality of non-users. GLP-1 users were less likely to present with advanced colon cancer symptoms such as sepsis and had fewer strokes and heart attacks during follow-up. The association persisted after controlling for comorbidities including depression and kidney disease. GLP-1 drugs lower systemic inflammation through multiple pathways and have known metabolic and cardiovascular benefits. Reduced inflammation and possible tumor-starvation effects that turn off pro-cancer proteins are plausible mechanisms linking GLP-1 therapy to improved colon cancer survival.
Read at Business Insider
Unable to calculate read time
Collection
[
|
...
]